+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Meniere Disease (Ear Nose Throat Disorders) - Drugs In Development, 2021

  • ID: 5359561
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 43 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Adare Pharma Solutions
  • Apsen Farmaceutica SA
  • IntraBio Ltd
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Steel Therapeutics Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Meniere Disease (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 1, 3, 1 and 1 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adare Pharma Solutions
  • Apsen Farmaceutica SA
  • IntraBio Ltd
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Steel Therapeutics Inc
  • MORE
Introduction
  • Report Coverage
Meniere Disease - Overview

Meniere Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Meniere Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Meniere Disease - Companies Involved in Therapeutics Development
  • Adare Pharma Solutions
  • Apsen Farmaceutica SA
  • IntraBio Ltd
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Steel Therapeutics Inc
  • Synphora AB
Meniere Disease - Drug Profiles

APSLXR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
betamethasone valerate ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Drug for Meniere's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ebselen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
IB-2000s - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
latanoprost - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
QPHL-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Meniere Disease - Dormant Projects

Meniere Disease - Product Development Milestones

Featured News & Press Releases
  • Jun 08, 2020: Sound Pharma advances pivotal Phase 3 clinical trials in Meniere's Disease
  • Sep 18, 2019: FDA grants Fast Track Designation for SPI-1005 in the treatment of Meniere's Disease
  • Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
  • Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
  • Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
  • Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
  • Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere's Disease clinical trial
  • Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
  • Jan 05, 2016: FDA allows Sound Pharmaceuticals to begin Meniere Disease clinical trial
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Meniere Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Meniere Disease - Pipeline by Adare Pharma Solutions, 2021
  • Meniere Disease - Pipeline by Apsen Farmaceutica SA, 2021
  • Meniere Disease - Pipeline by IntraBio Ltd, 2021
  • Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, 2021
  • Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, 2021
  • Meniere Disease - Pipeline by Steel Therapeutics Inc, 2021
  • Meniere Disease - Pipeline by Synphora AB, 2021
  • Meniere Disease - Dormant Projects, 2021
List of Figures
  • Number of Products under Development for Meniere Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Adare Pharma Solutions
  • Apsen Farmaceutica SA
  • IntraBio Ltd
  • Quark Pharmaceuticals Inc
  • Sound Pharmaceuticals Inc
  • Steel Therapeutics Inc
  • Synphora AB
Note: Product cover images may vary from those shown
Adroll
adroll